Definitive Healthcare Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on November 1, 2024, by Definitive Healthcare Corp. (DH), a Delaware corporation. The filing primarily addresses corporate governance changes, a new stock repurchase program, and references the announcement of financial results for the third quarter ended September 30, 2024, which was issued via press release on November 7, 2024.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed within the body of this 8-K.
Material Changes and Corporate Actions
- Executive Departure: Richard Booth, Chief Financial Officer, will leave the company effective June 1, 2025. The Board determined this departure constitutes a termination without "cause."
- Retention Incentive: Mr. Booth was awarded 92,379 time-vesting restricted stock units (RSUs) effective November 5, 2024, vesting on November 1, 2025, contingent on continued service.
- Stock Repurchase Program: The Board authorized a new program to repurchase up to $100.0 million of Class A Common Stock, expiring December 31, 2025. This follows the completion of a prior $20.0 million program. No repurchases had been made under the new program as of November 7, 2024.
- Voting Agreement: A voting agreement was entered into with Advent International. Advent agreed to vote shares exceeding 40.3% of outstanding voting securities (resulting from the repurchase program) in proportion to votes cast by other stockholders.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a detailed risk factor analysis. The stock repurchase program may be suspended or discontinued at the company's discretion. The search for a CFO successor is underway.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2024 revenue, earnings, and cash flow figures.
- Monitor the timeline for the appointment of a new Chief Financial Officer prior to June 1, 2025.
- Track the execution of the $100.0 million stock repurchase program and its impact on share count.
- Verify the implications of the voting agreement with Advent International on future shareholder votes.